Brucato, Gary
Appelbaum, Paul S.
Masucci, Michael D.
Rolin, Stephanie
Wall, Melanie M.
Levin, Mark
Altschuler, Rebecca
First, Michael B.
Lieberman, Jeffrey A.
Girgis, Ragy R.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (2KL2RR024157, K23MH066279, R21MH086125, R01P50MH086385, R01MH093398-01)
Brain and Behavior Research Foundation
Lieber Center for Schizophrenia Research
Same as Brucato
Article History
Received: 19 September 2018
Revised: 14 December 2018
Accepted: 16 December 2018
First Online: 27 December 2018
Competing interests
: R.G. acknowledges receiving research support from Otsuka, Allergan/Forest, BioAvantex, and Genentech. J.L. has received support administered through his institution in the form of funding or medication supplies for investigator initiated research from Lilly, Denovo, Biomarin, Novartis, Taisho, Teva, Alkermes, and Boehringer Ingelheim, and is a member of the advisory board of Intracellular Therapies and Pierre Fabre. He neither accepts nor receives any personal financial remuneration for consulting, advisory board or research activities. He holds a patent from Repligen and receives royalty payments from “SHRINKS: The Untold Story of Psychiatry.” The remaining authors declare no competing interests.